Quantification of galantamine in human plasma by validated liquid chromatography-tandem mass spectrometry using glimepride as an internal standard: Application to bioavailability studies in 32 healthy korean subjects

Journal of Chromatographic Science

Volumn 50, Issue 9, 2012, Pages 803-809

  Park, Yoo Sin ^a,b,c   Kim, Shin Hee ^a,b,c   Kim, Sang Yeon ^a,b,c   Kim, Youn Hee ^d   Lee, Min Ho ^e   Yang, Seok Chul ^f   Shaw, Leslie M ^g   Kang, Ju Seop ^a,b,c  

^a Department of Biochemistry and Molecular Biology   (South Korea)

^b Hanyang Biomedical Research Institute   (South Korea)

^c Hanyang University   (South Korea)

^d Heartscan Healthcare   (South Korea)

^e Hanyang University College of Medicine   (South Korea)

^f Seoul National University Hospital   (South Korea)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GALANTAMINE; GLIMEPIRIDE; SULFONYLUREA DERIVATIVE;

ADULT; ARTICLE; BIOAVAILABILITY; BLOOD; CHEMISTRY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIQUID LIQUID EXTRACTION; MALE; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; REPRODUCIBILITY; REVERSED PHASE LIQUID CHROMATOGRAPHY; SENSITIVITY AND SPECIFICITY; SOUTH KOREA; TANDEM MASS SPECTROMETRY; THERAPEUTIC EQUIVALENCE;

ADULT; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, REVERSE-PHASE; CROSS-OVER STUDIES; GALANTAMINE; HUMANS; LEAST-SQUARES ANALYSIS; LIQUID-LIQUID EXTRACTION; MALE; REPRODUCIBILITY OF RESULTS; REPUBLIC OF KOREA; SENSITIVITY AND SPECIFICITY; SULFONYLUREA COMPOUNDS; TANDEM MASS SPECTROMETRY; THERAPEUTIC EQUIVALENCY;

EID: 84867788258     PISSN: 00219665     EISSN: None     Source Type: Journal    
DOI: 10.1093/chromsci/bms074     Document Type: Article

References (39)

1. Coyle, J., Kershaw, P.; Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: Effects on the course of Alzheimer's disease; Biological Psychiatry, (2001); 49: 289-299. (Pubitemid 32178438)
2. Erkinjuntti, T.; Treatment options: The latest evidence with galantamine (Reminyl); Journal of the Neurological Sciences, (2002); 15: 125-130. (Pubitemid 35287387)
3. Farlow, M.R.; Clinical pharmacokinetics of galantamine. Clinical Pharmacokinetics, (2003); 42(15): 1383-1392. (Pubitemid 38045842)
4. Woodruff-Pak, D.S., Vogel, R.W., III, Wenk, G.L.; Galantamine: Effect on nicotinic receptor binding, acetylcholinesterase inhibition, and learning; Proceedings of the National Academy of Science, (2001); 98(4): 2089-2094. (Pubitemid 32165627)
5. Baraka, A., Harik, S.; Reversal of central anticholinergic syndrome by galanthamine; Journal of the American Medical Association, (1977); 238(21): 2293-2294. (Pubitemid 8259814)
6. De Angelis, J., Walts, L.F.; Comparison of galanthamine with neostigmine for reversal of d-tubocurarineneuromuscular blockade in man; Anesthesia and Analgesia, (1972); 51(2): 196-199.
7. Raskind, M.A., Peskind, E.R., Wessel, T., Yuan, W.; Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group; Neurology, (2000); 54(12): 2261-2268. (Pubitemid 30416276)
8. Wilcock, G.K., Lilienfeld, S., Gaens, E.; Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: Multicentre randomized controlled trial. Galantamine International-1 Study Group. BMJ, (2000); 321(7274): 1445-1449.
9. Rockwood, K., Mintzer, J., Truyen, L., Wessel, T., Wilkinson, D.; Effects of a flexible galantamine dose in Alzheimer's disease: A randomized, controlled trial; Journal of Neurology, Neurosurgery and Psychiatry, (2001); 71(5): 589-595. (Pubitemid 33010571)
10. Erkinjuntti, T., Kurz, A., Gauthier, S., Bullock, R., Lilienfeld, S., Damaraju, C.V.; Efficacy of galantamine in probable vascular dementia Alzheimer's disease combined with cerebrovascular disease: A randomized trial; Lancet, (2002); 359(9314): 1283-1290. (Pubitemid 34310633)
11. Tariot, P.N., Solomon, P.R, Morris, J.C., Kershaw, P., Lilienfeld, S., Ding, C.; A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology, (2000); 54(12): 2269-2276.
12. Jones, R.W., Cooper, D.M., Haworth, J., Langford, H., Fox, J.; The effect of food on the absorption of galantamine in healthy elderly volunteers; British Journal of Clinical Pharmacology, (1996); 42: 671.
13. Bachus, R., Bickel, U., Thomsen, T., Roots, I., Kewitz, H.; The O-demethylation of the antidementia drug galantamine is catalysed by cytochrome P450 2D6; Pharmacogenetics, (1999); 9(6): 661-668. (Pubitemid 30011930)
14. Mannens, G.S.J., Snel, C.A.W., Hendrickx, J., Verhaeghe, T., Le Jeune, L., Bode, W., et al.; The metabolism and excretion of galantamine in rats, dogs, and humans; Drug Metabolism and Disposition, (2002); 30(5): 553-563. (Pubitemid 34456978)
15. Zhao, Q., Iyer, G.R., Verhaeghe, T., Truyen, L.; Pharmacokinetics and safety of galantamine in subjects with hepatic impairment and healthy volunteers; Journal of Clinical Phamacology, (2002); 42(4): 428-436. (Pubitemid 34259777)
16. Mihailova, D., Yamboliev, I., Zhivkova, Z., Tencheva, J., Jovovich, V.; Pharmacokinetics of galanthamine hydrobromide after single subcutaneous and oral dosage in humans; Pharmacology, (1989); 39(1): 50-58. (Pubitemid 19204543)
17. Bickel, U., Thomsen, T., Weber, W., Fischer, J.P., Bachus, R., Nitz, M., et al.; Pharmacokinetics of galanthamine in humans and corresponding cholinesterase inhibition; Clinical Pharmacology and Therapeutics, (1991); 50(4): 420-428.
18. Scott, L.J., Goa, K.L.; Gelatamine: A review of its use in Alzheimer's disease; Drugs, (2000); 60(5): 1095-1122.
19. Kewtiz, H.; Pharmacokinetics and metabolism of galanthamine. Drugs Today, (1997); 33: 265-272.
20. Rizzi, A., Schuh, R., Bruckner, A., Cvitkovich, B., Kremser, L., Jordis, U., et al.; Enantiomeric resolution of galanthamine and related drugs used in anti-Alzheimer therapy by means of capillary zone electrophoresis employing derivatized cyclodextrin selectors; Journal of Chromatography B, (1999); 730(2): 167-175. (Pubitemid 29308882)
21. Claessens, H.A., Van Thiel, M., Westra, P., Soeterboek, A.M.; High-performance liquid chromatographic determination of galantamine, a long-acting anticholinesterase drug, in serum, urine and bile; Journal of Chromatography, (1983); 275(2): 345-353. (Pubitemid 13077888)
22. Tencheva, J., Yamboliev, I., Zhivkova, J.; Reversed-phase liquid chromatography for the determination of galanthamine and its metabolites in human plasma and urine; Journal of Chromatography, (1987); 421(2): 396-400. (Pubitemid 17158071)
23. Monbaliu, J., Verhaeghe, T., Williems, B., Bode, W., Lavrijsen, K., Meuldermans, W.; Pharmacokinetics of galantamine, a cholinesterase inhibitor, in several animal species; Arzneimittelforschung, (2003); 53(7): 486-495. (Pubitemid 36918533)
24. Verhaeghe, T., Diels, R., De Meuler, M., de Jong, J.; Development and validation of a liquid chromatographic-tandem mass spectrometric method for the determination of galantamine in human heparinised plasma; Journal of Chromatography B, (2003); 789(2): 337-346. (Pubitemid 36549202)
25. Malakova, J., Nobilis, M., Svoboda, Z., Lisa, M., Holcapek, M., Kvetina, J., et al.; High-performance liquid chromatographic method with UV photodiode-array, fluorescence and mass spectrometric detection for simultaneous determination of galantamine and its phase I metabolites in biological samples; Journal of Chromatography B, (2007); 853(1-2): 265-274. (Pubitemid 46891366)
26. Nirogi, R.V., Kandikere, V.N., Mudigonda, K., Maurya, S.; Quantitative determination of galantamine in human plasma by sensitive liquid chromatography-tandem mass spectrometry using loratadine as an internal standard; Journal of Chromatographic Science, (2007); 45(2): 97-103. (Pubitemid 46207398)
27. Jemal, M.; High-throughput quantitative bioanalysis by LC/MS/MS; Biomedical Chromatography, (2000); 14(6): 422-429.
28. Guidance for industry: Bioanalytical method validation. U.S. Department of Health and Human Service, Food and Drug Administration, Rockville, MD, (2001).
29. Merves, M.L., Goldberger, B.A.; Chromatographic methods in clinical chemistry and toxicology, Chapter 1. Bertholf, R.L., Winecker, R.E., (eds). John Wiley & Sons, Chichester, UK, (2007).
30. Merves, M.L., Goldberger, B.A. Quality assurance, quality control and method validation in chromatographic applications. In Chromatographic methods in clinical chemistry and toxicology. Bertholf, R.L., Winecker, R.E. John Wiley & Sons, Chichester, UK, (2007)
31. Goodyear, M.D., Krleza-Jeric, K., Lemmens, T.; Declaration of Helsinki; BMJ, (2007); 335(7621): 624-625.
32. ICH Topic E6; Guideline for good clinical practice. The European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Uni, ICH, Geneva, Switzerland, (2002). http://www. emea.eu.int/ (accessed January 12, 2011).
33. Yamaoka, K., Tanigawara, Y., Nakagawa, T., Uno, T.; A pharmacokinetic analysis program (multi) for microcomputer; Journal of Pharmacobiodynamics, (1981); 4(11): 879-885. (Pubitemid 12174128)
34. Shargel, L., Wu-Pong, S., Yu, A.; Applied biopharmaceutics & pharmacokinetics, 5th edition. McGraw Hill, New, York, NY, (2005), pp. 161.
35. Burton, M.E., Shaw, L.M., Schentag, J.J., Evans, W.E.; Applied pharmacokinetics and pharmacodynamics; Principles of therapeutic drug monitoring, 4th edition. Beringer, P.M. Lippincott Williams & Wilkins, Baltimore, MD, (2005).
36. PK Solutions 2.0 software: Noncompartmental pharmacokinetic data analysis. Summit Research Services, Montrose, CO, (2005).
37. Ritschel, W.A.; Handbook of basic pharmacokinetics, Drug intelligence, 4th edition. Hamilton Press, Hamilton, IL, (1992), pp. 27.
38. Martindale, The complete drug reference, 34th edition. Pharmaceutical Press, London, (2008), pp. 1491.
39. Zhang, L.J., Fang, X.L., Li, X.N., Wang, Q.S., Han, L.M., Zhang, Z.W., et al.; Phaimacokinetics and bioequivalence studies of galantamine hydrobromide dispersible tablet in healthy male Chinese volunteers; Drug Development and Industrial Pharmacy, (2007); 33(3): 335-340.